Annual Cash & Cash Equivalents
$13.39 B
+$5.88 B+78.17%
31 December 2023
Summary:
Novartis AG annual cash & cash equivalents is currently $13.39 billion, with the most recent change of +$5.88 billion (+78.17%) on 31 December 2023. During the last 3 years, it has risen by +$3.73 billion (+38.67%). NVS annual cash & cash equivalents is now at all-time high.NVS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$13.61 B
+$5.71 B+72.20%
30 September 2024
Summary:
Novartis AG quarterly cash and cash equivalents is currently $13.61 billion, with the most recent change of +$5.71 billion (+72.20%) on 30 September 2024. Over the past year, it has increased by +$1.20 billion (+9.71%). NVS quarterly cash and cash equivalents is now -15.98% below its all-time high of $16.20 billion, reached on 30 June 2008.NVS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVS Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +78.2% | +9.7% |
| 3 y3 years | +38.7% | +88.7% |
| 5 y5 years | +0.9% | +62.4% |
NVS Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +78.2% | -1.8% | +275.4% |
| 5 y | 5 years | at high | +78.2% | -1.8% | +275.4% |
| alltime | all time | at high | +557.2% | -16.0% | +567.8% |
Novartis AG Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $13.61 B(+72.2%) |
| June 2024 | - | $7.90 B(-16.5%) |
| Mar 2024 | - | $9.47 B(-29.3%) |
| Dec 2023 | $13.39 B(+78.2%) | $13.39 B(+8.0%) |
| Sept 2023 | - | $12.40 B(+14.0%) |
| June 2023 | - | $10.88 B(-9.3%) |
| Mar 2023 | - | $12.00 B(+59.6%) |
| Dec 2022 | $7.52 B(-39.4%) | $7.52 B(-13.9%) |
| Sept 2022 | - | $8.73 B(+140.7%) |
| June 2022 | - | $3.63 B(-73.8%) |
| Mar 2022 | - | $13.85 B(+11.6%) |
| Dec 2021 | $12.41 B(+28.5%) | $12.41 B(+72.1%) |
| Sept 2021 | - | $7.21 B(+40.9%) |
| June 2021 | - | $5.12 B(+34.6%) |
| Mar 2021 | - | $3.80 B(-60.6%) |
| Dec 2020 | $9.66 B(-13.1%) | $9.66 B(+7.4%) |
| Sept 2020 | - | $8.99 B(+52.0%) |
| June 2020 | - | $5.92 B(+30.7%) |
| Mar 2020 | - | $4.53 B(-59.3%) |
| Dec 2019 | $11.11 B(-16.3%) | $11.11 B(+32.6%) |
| Sept 2019 | - | $8.38 B(-16.1%) |
| June 2019 | - | $9.99 B(+46.8%) |
| Mar 2019 | - | $6.81 B(-48.7%) |
| Dec 2018 | $13.27 B(+49.8%) | $13.27 B(-5.2%) |
| Sept 2018 | - | $14.00 B(+12.5%) |
| June 2018 | - | $12.45 B(+114.1%) |
| Mar 2018 | - | $5.81 B(-34.4%) |
| Dec 2017 | $8.86 B(+26.4%) | $8.86 B(+26.4%) |
| Dec 2016 | $7.01 B(+49.9%) | $7.01 B(+49.9%) |
| Dec 2015 | $4.67 B(-64.1%) | $4.67 B(-64.1%) |
| Dec 2014 | $13.02 B(+94.8%) | $13.02 B(+94.8%) |
| Dec 2013 | $6.69 B(+20.4%) | $6.69 B(+20.4%) |
| Dec 2012 | $5.55 B(+49.7%) | $5.55 B(+49.7%) |
| Dec 2011 | $3.71 B(-30.3%) | $3.71 B(-30.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2010 | $5.32 B(+83.8%) | $5.32 B(+83.8%) |
| Dec 2009 | $2.89 B(+42.0%) | $2.89 B(+42.0%) |
| Dec 2008 | $2.04 B(-62.0%) | $2.04 B(-75.0%) |
| Sept 2008 | - | $8.14 B(-49.8%) |
| June 2008 | - | $16.20 B(+49.3%) |
| Mar 2008 | - | $10.85 B(+102.4%) |
| Dec 2007 | $5.36 B(+40.5%) | $5.36 B(-63.1%) |
| Sept 2007 | - | $14.53 B(+92.5%) |
| June 2007 | - | $7.55 B(+8.5%) |
| Mar 2007 | - | $6.96 B(+82.4%) |
| Dec 2006 | $3.81 B(-39.6%) | $3.81 B(-55.3%) |
| Sept 2006 | - | $8.53 B(+16.7%) |
| June 2006 | - | $7.31 B(-34.2%) |
| Mar 2006 | - | $11.12 B(+75.9%) |
| Dec 2005 | $6.32 B(+3.9%) | $6.32 B(-20.5%) |
| Sept 2005 | - | $7.95 B(-15.8%) |
| June 2005 | - | $9.44 B(-23.1%) |
| Mar 2005 | - | $12.28 B(+101.9%) |
| Dec 2004 | $6.08 B(+7.7%) | $6.08 B(+91.3%) |
| Sept 2004 | - | $3.18 B(-10.9%) |
| June 2004 | - | $3.57 B(+9.9%) |
| Mar 2004 | - | $3.25 B(-42.5%) |
| Dec 2003 | $5.65 B(-2.6%) | $5.65 B(+20.5%) |
| Sept 2003 | - | $4.68 B(+2.9%) |
| June 2003 | - | $4.55 B(-23.8%) |
| Mar 2003 | - | $5.97 B(+3.0%) |
| Dec 2002 | $5.80 B(-13.8%) | $5.80 B(-43.9%) |
| Sept 2002 | - | $10.33 B(-19.9%) |
| June 2002 | - | $12.90 B(+91.8%) |
| Dec 2001 | $6.73 B(+23.3%) | $6.73 B(+155.0%) |
| June 2001 | - | $2.64 B(-51.6%) |
| Dec 2000 | $5.45 B(+38.3%) | $5.45 B(+59.5%) |
| June 2000 | - | $3.42 B |
| Dec 1999 | $3.94 B(-18.4%) | - |
| Dec 1998 | $4.83 B | - |
FAQ
- What is Novartis AG annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Novartis AG?
- What is Novartis AG annual cash & cash equivalents year-on-year change?
- What is Novartis AG quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Novartis AG?
- What is Novartis AG quarterly cash and cash equivalents year-on-year change?
What is Novartis AG annual cash & cash equivalents?
The current annual cash & cash equivalents of NVS is $13.39 B
What is the all time high annual cash & cash equivalents for Novartis AG?
Novartis AG all-time high annual cash & cash equivalents is $13.39 B
What is Novartis AG annual cash & cash equivalents year-on-year change?
Over the past year, NVS annual cash & cash equivalents has changed by +$5.88 B (+78.17%)
What is Novartis AG quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NVS is $13.61 B
What is the all time high quarterly cash and cash equivalents for Novartis AG?
Novartis AG all-time high quarterly cash and cash equivalents is $16.20 B
What is Novartis AG quarterly cash and cash equivalents year-on-year change?
Over the past year, NVS quarterly cash and cash equivalents has changed by +$1.20 B (+9.71%)